Normalizing air-sea flux coefficients for horizontal homogeneity, stationarity, and neutral stratification
No abstract prepared.
SEARCH · Engineering Papers
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
No abstract prepared.
No abstract prepared.
We aimed to refine the value of CDX 2 as an independent prognostic and predictive biomarker in colorectal cancer ( CRC ) according to disease stage and chemotherapy sensitivity in preclinical models. CDX 2 expression was evaluated in 1045 stage I– IV primary CRC s by gene expression ( n = 403) or immunohistochemistry ( n = 642) and in relation to 5‐year relapse‐free survival ( RFS ), overall survival ( OS ), and chemotherapy. Pharmacogenomic associations between CDX 2 expression and 69 chemotherapeutics were assessed by drug screening of 35 CRC cell lines. CDX 2 expression was lost in 11.6% of cases and showed independent poor prognostic value in multivariable models. For individual stages, CDX 2 was prognostic only in stage IV , independent of chemotherapy. Among stage I– III patients not treated in an adjuvant setting, CDX 2 loss was associated with a particularly poor survival in the BRAF ‐mutated subgroup, but prognostic value was independent of microsatellite instability status and the consensus molecular subtypes. In stage III , the 5‐year RFS rate was higher among patients with loss of CDX 2 who received adjuvant chemotherapy than among patients who did not. The CDX 2‐negative cell lines were significantly more sensitive to chemotherapeutics than CDX 2‐positive cells, and the multidrug resistance genes MDR 1 and CFTR were significantly downregulated both in CDX 2‐negative cells and in patient tumors. Loss of CDX 2 in CRC is an adverse prognostic biomarker only in stage IV disease and appears to be associated with benefit from adjuvant chemotherapy in stage III . Early‐stage patients not qualifying for chemotherapy might be reconsidered for such treatment if their tumor has loss of CDX 2 and mutated BRAF .
In previous work, commercially available downward facing exploding bridgewire detonators (EBWs) were exposed to elevated temperatures. These detonators were then initiated using a firing set which discharged a high amplitude short duration electrical pulse into a thin gold bridgewire. Responses of the detonators were measured using photonic doppler velocimetry (PDV) and high-speed photography. A time delay of 4 μs between EBW initiation and first movement of an output flyer separated operable detonators from inoperable detonators or duds. Here, we propose a simple method to determine detonator operability from the calculated state of the detonator at the time the firing set is initiated. The failure criterion is based on the gap distance between the exploding bridgewire (EBW) and the adjacent initiating explosive within the detonator which is low-density pentaerythritol tetranitrate (PETN) that melts between 413-415 K (140-142 ºC). The gap forms as PETN melts and flows to the bottom of the input pellet. Melting of PETN is modeled thermodynamically as an energy sink using a normal distribution spread over a temperature range between the onset temperature of 413 K and the ending temperature of 415 K. The extent of the melt is determined from the average temperature of the PETN. The PETN liquid is assumed to occupy the interstitial gas volume in the lower part of the input pellet. The vacated volume from the relocated liquid forms the gap between the EBW and the PETN. The remaining sandwiched layer consists of solid PETN particles and gas filling interstitial volume. We predict that a threshold gap between 17-27 μm separates properly functioning detonators from duds.
We show that a master integrand basis exists for all planar, two-loop amplitudes in massless four-dimensional theories which is fully stratified by rigidity — with each integrand being either pure and strictly polylogarithmic or (pure and) strictly elliptic-polylogarithmic, with each of the later involving a single elliptic curve. Such integrands can be said to have definite rigidity.
Not provided.
Background: Assessment of infarct size after myocardial infarction is predictive of subsequent morphological changes and clinical outcome. This study aimed to assess subacute post-intervention Rubidium-82 ({sup 82}Rb)-PET imaging in predicting left ventricle ejection fraction, regional wall motion, and final infarct size by CMR at 3-months after STEMI. Methods: STEMI patients undergoing percutaneous coronary intervention were included prospectively. Rest-only {sup 82}Rb-PET perfusion imaging was performed at median 36 hours [IQR: 22 to 50] after the treatment. The extent of hypoperfusion and absolute blood flow (mL·min·g) were estimated on a global and a 17-segment model with dedicated software. At 3-months follow-up patients completed the CMR functional and late gadolinium enhancement imaging. Results: 42 patients were included, but only 35 had follow-up CMR and constituted the study population. Absolute blood flow was significantly lower in the infarct-related territory compared to remote myocardium, P < .005. Extent of hypoperfusion correlated with final infarct size, r = 0.58, P < .001, while blood flow correlated with ejection fraction, r = 0.41, P < .05. In linear mixed models, higher subacute absolute blood flow (β = 4.6, confidence interval [3.5; 5.2], P < .001, R{sup 2} = 0.67) was associated with greater wall motion. Segmental extent of subacute hypoperfusion (β = 0.43 [0.38; 0.49], P < .001, R{sup 2} = 0.58) was associated with the degree of late gadolinium enhancement at 3-months. Conclusions: Subacute rest-only {sup 82}Rb-PET is feasible following STEMI and seems predictive of myocardial function and infarct size at 3-months.
No abstract prepared.
Not Available
Not provided.
Not Available
Not Available
Purpose: To compare prostate-specific antigen (PSA) outcomes in a cohort of men with high-risk prostate cancer based on the presence or absence of any Gleason Grade 5 component (primary, secondary, or tertiary). Methods and Materials: Our study cohort consisted of 312 men with T1c-T3N0M0 prostate cancer with Gleason Scores of 7 with tertiary Grade 5, 8, or 9-10 who underwent radical prostatectomy or external beam radiotherapy with or without androgen suppression therapy. Cox regression multivariable analysis was used to assess whether a difference existed in risk of PSA recurrence in men with Gleason Score of 9-10 compared with those with Gleason Score of 8 and 7 with tertiary Grade 5, adjusting for treatment, age, and known prostate cancer prognostic factors. Results: After a median follow-up of 5.7 years, men with a Gleason Score of 8 had a lower risk of PSA recurrence than those with a Gleason Score of 9-10 (hazard ratio, 0.74; 95% confidence interval, 0.52-1.05; p = 0.09). Conversely, men with a Gleason Score of 7 with tertiary Grade 5 had a similar risk of PSA recurrence compared with men with a Gleason Score of 9-10 (hazard ratio, 1.08; 95% confidence interval, 0.60-1.94; p = 0.81). Median times to PSA failure for men with Gleason Scores of 9-10, 7 with tertiary Grade 5, and 8 were 4.5, 5.0, and 5.4 years, respectively. Conclusions: Our results highlight the importance of further substratification of the high-risk Gleason Score category of 8-10 into 8 vs. 9, 10, and 7 with tertiary Grade 5.
Purpose: To evaluate the primary Gleason grade (GG) in Gleason score (GS) 7 prostate cancers for risk of non-organ-confined disease with the goal of optimizing radiotherapy treatment option counseling. Methods: One thousand three hundred thirty-three patients with pathologic GS7 were identified in the Duke Prostate Center research database. Clinical factors including age, race, clinical stage, prostate-specific antigen at diagnosis, and pathologic stage were obtained. Data were stratified by prostate-specific antigen and clinical stage at diagnosis into adapted D'Amico risk groups. Univariate and multivariate analyses were performed evaluating for association of primary GG with pathologic outcome. Results: Nine hundred seventy-nine patients had primary GG3 and 354 had GG4. On univariate analyses, GG4 was associated with an increased risk of non-organ-confined disease. On multivariate analysis, GG4 was independently associated with seminal vesicle invasion (SVI) but not extracapsular extension. Patients with otherwise low-risk disease and primary GG3 had a very low risk of SVI (4%). Conclusions: Primary GG4 in GS7 cancers is associated with increased risk of SVI compared with primary GG3. Otherwise low-risk patients with GS 3+4 have a very low risk of SVI and may be candidates for prostate-only radiotherapy modalities.
Purpose: Brachytherapy after lumpectomy is an increasingly popular breast cancer treatment, but data concerning its effectiveness are conflicting. Recently proposed “suitability” criteria guiding patient selection for brachytherapy have never been empirically validated. Methods: Using the Surveillance, Epidemiology, and End Results–Medicare linked database, we compared women aged 66 years or older with invasive breast cancer (n=28,718) or ductal carcinoma in situ (n=7229) diagnosed from 2002 to 2007, treated with lumpectomy alone, brachytherapy, or external beam radiation therapy (EBRT). The likelihood of breast preservation, measured by subsequent mastectomy risk, was compared by use of multivariate proportional hazards, further stratified by American Society for Radiation Oncology (ASTRO) brachytherapy suitability groups. We compared 1-year postoperative complications using the χ{sup 2} test and 5-year local toxicities using the log-rank test. Results: For patients with invasive cancer, the 5-year subsequent mastectomy risk was 4.7% after lumpectomy alone (95% confidence interval [CI], 4.1%-5.4%), 2.8% after brachytherapy (95% CI, 1.8%-4.3%), and 1.3% after EBRT (95% CI, 1.1%-1.5%) (P<.001). Compared with lumpectomy alone, brachytherapy achieved a more modest reduction in adjusted risk (hazard ratio [HR], 0.61; 95% CI, 0.40-0.94) than achieved with EBRT (HR, 0.22; 95% CI, 0.18-0.28). Relative risks did not differ when stratified by ASTRO suitability group (P=.84 for interaction), although ASTRO “suitable” patients did show a low absolute subsequent mastectomy risk, with a minimal absolute difference in risk after brachytherapy (1.6%; 95% CI, 0.7%-3.5%) versus EBRT (0.8%; 95% CI, 0.6%-1.1%). For patients with ductal carcinoma in situ, EBRT maintained a reduced risk of subsequent mastectomy (HR, 0.40; 95% CI, 0.28-0.55; P<.001), whereas the small number of patients treated with brachytherapy (n=179) precluded definitive comparison with lumpectomy alone. In all patients, brachytherapy showed a higher postoperative infection risk (16.5% vs 9.9% after lumpectomy alone vs 11.4% after EBRT, P<.001); higher incidence of breast pain (22.9% vs 11.2% vs 16.7%, P<.001); and higher incidence of fat necrosis (15.3% vs 5.3% vs 7.7%, P<.001). Conclusions: In this study era, brachytherapy showed lesser breast preservation benefit compared with EBRT. Suitability criteria predicted differential absolute, but not relative, benefit in patients with invasive cancer.
No abstract prepared.
To predict overall survival of patients receiving stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (ES-NSCLC), we developed a radiomic model that integrates risk of death estimates and changes based on pre- and posttreatment computed tomography (CT) scans. We hypothesize this innovation will improve our ability to stratify patients into various oncologic outcomes with greater accuracy.